BACKGROUND & AIMS: Chemokines, such as CXCR3-ligands, have been identified to play an important role during hepatic injury, inflammation and fibrosis. While CXCL9 is associated with survival in patients receiving transjugular intrahepatic portosystemic shunt (TIPS), the role of CXCL11 in severe portal hypertension remains unknown. METHODS: CXCL11-levels were measured in 136 patients with liver diseases, and 63 healthy controls. In further 47 cirrhotic patients receiving TIPS, CXCL11 levels were measured in portal and hepatic veins at TIPS insertion by cytometric bead array. CXCL11-levels were measured in 23 patients in cubital vein and right atrium, whereas in 24 patients in portal and hepatic blood at an invasive reevaluation. RESULTS: CXCL11-levels were increased with the severity of liver fibrosis. CXCL11-levels from portal, hepatic and cubital veins and right atrium showed a highly significant correlation among each other in these patients. Furthermore, levels of CXCL11 from the right atrium were significantly higher than those from cubital vein. Interestingly, patients with alcoholic cirrhosis had significantly lower CXCL11-levels, than other aetiologies of cirrhosis. After TIPS, CXCL11 levels correlated with the degree of portal pressure and patients with higher CXCL11-levels in portal and hepatic veins showed higher mortality. Multivariate analysis revealed hepatic CXCL11-levels before TIPS, creatinine and age as independent predictors for survival in TIPS patients, whereas MELD score and low portal CXCL11-levels after TIPS predicted long-term survival. CONCLUSION: CXCL11 levels are mainly increased in patients with non-alcoholic cirrhosis and high portal pressure. Moreover, levels of CXCL11 might predict long-time survival of cirrhotic patients bearing TIPS.
BACKGROUND & AIMS: Chemokines, such as CXCR3-ligands, have been identified to play an important role during hepatic injury, inflammation and fibrosis. While CXCL9 is associated with survival in patients receiving transjugular intrahepatic portosystemic shunt (TIPS), the role of CXCL11 in severe portal hypertension remains unknown. METHODS:CXCL11-levels were measured in 136 patients with liver diseases, and 63 healthy controls. In further 47 cirrhotic patients receiving TIPS, CXCL11 levels were measured in portal and hepatic veins at TIPS insertion by cytometric bead array. CXCL11-levels were measured in 23 patients in cubital vein and right atrium, whereas in 24 patients in portal and hepatic blood at an invasive reevaluation. RESULTS:CXCL11-levels were increased with the severity of liver fibrosis. CXCL11-levels from portal, hepatic and cubital veins and right atrium showed a highly significant correlation among each other in these patients. Furthermore, levels of CXCL11 from the right atrium were significantly higher than those from cubital vein. Interestingly, patients with alcoholic cirrhosis had significantly lower CXCL11-levels, than other aetiologies of cirrhosis. After TIPS, CXCL11 levels correlated with the degree of portal pressure and patients with higher CXCL11-levels in portal and hepatic veins showed higher mortality. Multivariate analysis revealed hepatic CXCL11-levels before TIPS, creatinine and age as independent predictors for survival in TIPS patients, whereas MELD score and low portal CXCL11-levels after TIPS predicted long-term survival. CONCLUSION:CXCL11 levels are mainly increased in patients with non-alcoholic cirrhosis and high portal pressure. Moreover, levels of CXCL11 might predict long-time survival of cirrhotic patients bearing TIPS.
Authors: Michael Praktiknjo; Jennifer Lehmann; Mette J Nielsen; Robert Schierwagen; Frank E Uschner; Carsten Meyer; Daniel Thomas; Christian P Strassburg; Flemming Bendtsen; Søren Møller; Aleksander Krag; Morten A Karsdal; Diana J Leeming; Jonel Trebicka Journal: Hepatol Commun Date: 2018-01-18
Authors: Jennifer Lehmann; Michael Praktiknjo; Mette Juul Nielsen; Robert Schierwagen; Carsten Meyer; Daniel Thomas; Francesco Violi; Christian P Strassburg; Flemming Bendtsen; Søren Møller; Aleksander Krag; Morten Asser Karsdal; Diana Julie Leeming; Jonel Trebicka Journal: Liver Int Date: 2019-03-07 Impact factor: 5.828
Authors: Fabian Benz; Andreas Bogen; Michael Praktiknjo; Christian Jansen; Carsten Meyer; Alexander Wree; Muenevver Demir; Sven Loosen; Mihael Vucur; Robert Schierwagen; Frank Tacke; Jonel Trebicka; Christoph Roderburg Journal: PLoS One Date: 2020-04-17 Impact factor: 3.240
Authors: Robert Schierwagen; Frank E Uschner; Cristina Ortiz; Sandra Torres; Max J Brol; Olaf Tyc; Wenyi Gu; Christian Grimm; Stefan Zeuzem; Andreas Plamper; Philipp Pfeifer; Sebastian Zimmer; Christoph Welsch; Liliana Schaefer; Karl P Rheinwalt; Joan Clària; Vicente Arroyo; Jonel Trebicka; Sabine Klein Journal: Front Immunol Date: 2020-07-07 Impact factor: 7.561
Authors: Alexander Queck; Hannah Bode; Frank E Uschner; Maximilian J Brol; Christiana Graf; Martin Schulz; Christian Jansen; Michael Praktiknjo; Robert Schierwagen; Sabine Klein; Christian Trautwein; Hermann E Wasmuth; Marie-Luise Berres; Jonel Trebicka; Jennifer Lehmann Journal: Front Immunol Date: 2020-03-11 Impact factor: 7.561